All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Publication

Article

July 2, 2013

Pharmaceutical Technology

Pharmaceutical Technology-07-02-2013
Volume37
Issue 7

Navigating FDA Regulatory Meetings

David Elder, vice-president, technical at PAREXEL, discusses the best way to productively participate in a regulatory meeting with FDA.

Q. How can my company participate productively in a regulatory meeting with FDA?

A. An invitation to a regulatory meeting with FDA might not be preferred, but it isn't entirely negative. FDA management initiates a regulatory meeting to inform responsible individuals about how one or more products, practices, processes, or other activities are considered to be in violation of the law (1). FDA views regulatory meetings as another tool to achieve prompt, voluntary compliance, typically initiated either to advise and educate prior to a warning letter or to provide additional assistance or direction after a warning letter. In the former example, FDA may use the regulatory meeting tool to deal with small firms, new firms, firms with a good history of compliance, or firms who make lower-risk products. In the latter example, FDA may use the regulatory meeting after a follow-up re-inspection found progress but lack of full compliance—the meeting would be another attempt to achieve or accelerate compliance before determining that it is necessary to initiate an enforcement action (e.g., injunction, seizure).

David Elder

There are some steps that should be taken to maximize one's chances of a productive and successful regulatory meeting.

Preparation

  • Know the issues at hand and FDA's concerns.

  • Prepare a slide deck that outlines corrective actions planned and accomplished. Include sufficient substance on the corrections, including metrics, timelines, and accountability.

  • Be sure to address systemic corrective actions, and not merely spot fixes, to potentially larger problems that could span multiple product lines or even multiple manufacturing locations.

  • Think of the specific areas of concern and the potential questions that could be asked. Address them proactively in the presentation or be prepared to address them fully during discussions.

  • Inform FDA who will be in attendance and request a list of likely FDA participants. The list of company participants should be limited but clearly must include executive management and other managers with knowledge, responsibility, and accountability for the issues at hand.

Meeting action

  • The highest-ranking company official is generally in charge of the company's actions at the meeting, opens the presentation, and directs questions to other company officials with the expertise needed to answer them.

  • All company officials in attendance must be fully knowledgeable of the issues and the company's corrective action plan to present information or answer questions during the meeting.

  • When answering questions, listen carefully and be certain you understand the question to ensure your answer is responsive.

  • If a question cannot be answered by any company official present, then promise to respond as soon as possible after the meeting with the required information.

  • At no point of the meeting should the company seek to make excuses or defend past actions or decisions. The meeting is about moving forward with complete, systemic corrective actions to achieve and sustain compliance.

  • Each company official must be 100% truthful always, without exception, caveat, or nuance.

Follow through

  • Any open questions from the meeting should be addressed promptly, and periodic updates should continue as decided during the meeting.

  • The company's meeting minutes should be shared with FDA to ensure full and mutual understanding of all concerns and commitments.

  • Executive management must ensure that all commitments made in the meeting are completed on the timetable promised and that the company achieves and sustains substantial compliance with all laws and regulations.

  • Upon FDA's re-inspection, it must be clear that systemic corrective actions have been completed, that they are effective, that all commitments have been supported, and that the company is operating in substantial compliance with the law and regulations. Failure to live up to commitments after a regulatory meeting is a recipe for enforcement action.

A company's measure for success for a regulatory meeting should actually be quite consistent with FDA's measure for success: a clear commitment to address all concerns and to achieve and sustain compliance with the law and regulations.

Reference

1. FDA, Regulatory Procedures Manual, Section 10-3, 2011, www.fda.gov/ICECI/compliancemanuals/regulatoryproceduresmanual/default.htm#_top, accessed June 17, 2013.

Articles in this issue

Regulatory Roundup
Evaluating Risk-Based Specifications for Pharmaceuticals
Evaluating Risk-Based Specifications for Pharmaceuticals
Controlling Drug Release Through Osmotic Systems
Controlling Drug Release Through Osmotic Systems
Q&A with Claudia Roth, President, Vetter Development Service, USA
Q&A with Claudia Roth, President, Vetter Development Service, USA
Report from Brazil July 2013
Report from Brazil July 2013
i4-817349-1408540310627.jpg
Editors' picks of pharmaceutical science & technology innovations
i4-817346-1408540316784.jpg
Evaluating Parenteral Packaging for Glass Delamination
i1-817357-1408540293854.jpg
Navigating FDA Regulatory Meetings
i1-817356-1408540295573.jpg
EU Battles Medicine Shortages
i1-817347-1408540314813.jpg
USP Partners Globally for 21st-Century Medicines
Gauging Investment in High-Potency Manufacturing
Gauging Investment in High-Potency Manufacturing
i1-817352-1408540304288.jpg
What Happened to Outsourcing in Asia?
i1-817353-1408540302050.jpg
FDA Urges Greater Focus on Contractor Quality
i1-817345-1408540319498.jpg
Extractables and Leachables: Best Practices to Ensure Patient Safety
Strengthening the Supply Chain for Pharmaceutical Ingredients
Strengthening the Supply Chain for Pharmaceutical Ingredients

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Related Content
Advertisement
Futuristic health tech. A smartwatch projects a holographic health dashboard, providing real-time body analytics and vital signs monitoring anytime, anywhere. | Image Credit: © woravut - stock.adobe.com
August 5th 2025

How FDA’s ISTAND Initiative Supports Innovative Tools in Drug Discovery and Development

Patrick Lavery
The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial intelligence, wearables, and biomarkers in drug development and trials.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 5th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
Kratom or Mitragyna speciosa on natural background. | Image Credit: © wasanajai - stock.adobe.com
August 5th 2025

FDA Seeks Scheduling Action to Control Harmful Kratom Plant Byproduct

Patrick Lavery
7-OH and the leaf of the kratom plant are not analogous, but as the former is a derivative of the latter, it has opioid-like qualities that make its susceptibility to abuse concerning.
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 5th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.
automatic stainless steel pharmaceutical fermenter | Image Credit: ©gen_A - stock.adobe.com
August 5th 2025

In-line UV Spectrometry Monitoring in Cleaning Validation

John Schallom Brian Bosso Paul Lopolito Katie Frey Amy Thanavaro
The authors performed interference and enhancement testing using a formulated alkaline and acid cleaner, as well as common biopharmaceutical process residues.
Landkarte *** Europa | Image credit: ©beugdesign - Stock.adobe.com
August 5th 2025

EMA Encourages Use of New Approach Methodologies to Reduce Animal Testing

Cheryl Barton
EMA is phasing out animal testing and is asking pharmaceutical companies to use new approach methodologies.
Related Content
Advertisement
Futuristic health tech. A smartwatch projects a holographic health dashboard, providing real-time body analytics and vital signs monitoring anytime, anywhere. | Image Credit: © woravut - stock.adobe.com
August 5th 2025

How FDA’s ISTAND Initiative Supports Innovative Tools in Drug Discovery and Development

Patrick Lavery
The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial intelligence, wearables, and biomarkers in drug development and trials.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 5th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
Kratom or Mitragyna speciosa on natural background. | Image Credit: © wasanajai - stock.adobe.com
August 5th 2025

FDA Seeks Scheduling Action to Control Harmful Kratom Plant Byproduct

Patrick Lavery
7-OH and the leaf of the kratom plant are not analogous, but as the former is a derivative of the latter, it has opioid-like qualities that make its susceptibility to abuse concerning.
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 5th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.
automatic stainless steel pharmaceutical fermenter | Image Credit: ©gen_A - stock.adobe.com
August 5th 2025

In-line UV Spectrometry Monitoring in Cleaning Validation

John Schallom Brian Bosso Paul Lopolito Katie Frey Amy Thanavaro
The authors performed interference and enhancement testing using a formulated alkaline and acid cleaner, as well as common biopharmaceutical process residues.
Landkarte *** Europa | Image credit: ©beugdesign - Stock.adobe.com
August 5th 2025

EMA Encourages Use of New Approach Methodologies to Reduce Animal Testing

Cheryl Barton
EMA is phasing out animal testing and is asking pharmaceutical companies to use new approach methodologies.
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.